Latest Breaking News On - மைக்கேல் பார்ட்ரிட்ஜ் - Page 1 : comparemela.com
Eddie Partridge, legendary co-owner of Riverhead Raceway, dies at 68
newsday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newsday.com Daily Mail and Mail on Sunday newspapers.
Vertex Pharmaceuticals Incorporated: Vertex to Initiate Phase 3 Development Program for New Once-Daily Triple Combination Regimen in People With Cystic Fibrosis
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Power Of Intelligent Data Stitching – Hospitality Net
hospitalitynet.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hospitalitynet.org Daily Mail and Mail on Sunday newspapers.
Senior Vice President of Investor Relations
Good evening. Welcome to the Vertex First Quarter 2021 Financial Results Conference Call. This is Michael Partridge, Senior Vice President of Investor Relations for Vertex. Making prepared remarks on the call tonight, we have Dr. Reshma Kewalramani, Vertex s CEO and President; Stuart Arbuckle, Chief Commercial and Operations Officer and Charlie Wagner, Chief Financial Officer. We recommend that you access the webcast slides on our website as you listen to this call. This conference call is being recorded and a replay will be available on our website.
We will make forward-looking statements on this call that are subject to the risks and uncertainties discussed in detail in today s press release and in our filings with the Securities and Exchange Commission. These statements, including without limitation those regarding Vertex s marketed CF medicines, our pipeline, expectations regarding the closing of the CRISPR transaction, which is subje
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the .
CRISPR Therapeutics AGApril 26, 2021 GMT
BOSTON and CAMBRIDGE, Mass. and ZUG, Switzerland, April 26, 2021 (GLOBE NEWSWIRE) Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to CTX001, an investigational, autologous,
ex vivo CRISPR/Cas9 gene-edited therapy for the treatment of transfusion-dependent beta thalassemia (TDT). CTX001 was previously granted PRIME designation for the treatment of sickle cell disease (SCD) in 2020.